Page 81 - Vitamin D and Cancer

68 A.V. Krishnan and D. Feldman

71. Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R,
Buttyan R, Olsson CA (1999) Exisulind (sulindac sulfone) suppresses growth of human pros-
tate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53(2):440–445
72. Mifflin RC, Saada JI, Di Mari JF, Adegboyega PA, Valentich JD, Powell DW (2002)
Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-
mediated induction. Am J Physiol Cell Physiol 282(4):C824–C834
73. Chen Y, Hughes-Fulford M (2000) Prostaglandin E2 and the protein kinase A pathway medi-
ate arachidonic acid induction of c-fos in human prostate cancer cell. Br J Cancer
82(12):2000–2006
74. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S,
Willson JK, Luo G, Hensold J, Tai HH, Wilson K, Markowitz SD (2004) 15-Hydroxyprostaglandin
dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human
gastrointestinal cancers. Proc Natl Acad Sci USA 101(50):17468–17473
75. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ,
Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD (2006)
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
Proc Natl Acad Sci USA 103(32):12098–12102
76. Wolf I, O’Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, Koeffler HP
(2006) 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast can-
cer. Cancer Res 66(15):7818–7823
77. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes
and signaling. Annu Rev Pharmacol Toxicol 41:661–690
78. Tjandrawinata RR, Dahiya R, Hughes-Fulford M (1997) Induction of cyclo-oxygenase-2
mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 75(8):1111–1118
79. Tjandrawinata RR, Hughes-Fulford M (1997) Up-regulation of cyclooxygenase-2 by prod-
uct-prostaglandin E2. Adv Exp Med Biol 407:163–170
80. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M,
Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat
Med 6(9):1024–1028
81. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk ET, Kelloff
G, Lawson MJ, Kidao J, McCracken J, Albers G, Ahnen DJ, Turgeon K, Goldschmid S,
Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008) Difluoromethylornithine plus sulin-
dac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled,
double-blind trial. Cancer Prev Res 1:32–38
82. Sporn MB, Hong WK (2008) Clinical prevention of recurrence of colorectal adenomas by
the combination of difluoromethylornithine and sulindac: an important milestone. Cancer
Prev Res 1:9–11
83. Antman EM, DeMets D, Loscalzo J (2005) Cyclooxygenase inhibition and cardiovascular
risk. Circulation 112(5):759–770
84. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005)
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-
oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-
control study. Lancet 365(9458):475–481
85. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR (2002) COX-2 selec-
tive non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet
360(9339):1071–1073
86. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E,
Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J (2006) Effect of celecoxib on
cardiovascular events and blood pressure in two trials for the prevention of colorectal
adenomas. Circulation 114(10):1028–1035
87. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL,
Sorensen R, Folke F, Buch P, Gadsboll N, Rasmussen S, Poulsen HE, Kober L, Madsen M,
Torp-Pedersen C (2009) Increased mortality and cardiovascular morbidity associated with